Skip to main content
SpringerLink
Log in

Pharmakologische Therapie von prostatabedingten Miktionsstörungen

  • Chapter
Pharmakotherapie in der Urologie

  • 60 Accesses

Zusammenfassung

In Deutschland leiden etwa 30% aller Männer im Alter über 50 Jahren an behandlungsbedürftigen Miktionsstörungen, im allgemeinen als LUTS (Lower Urinary Tract Symptoms) bezeichnet. Der Anteil symptomatischer Männer steigt erwartungsgemäß mit dem Alter an: Während nur ein fünftel der 50- bis 69-jährigen behandlungsbedürftige Symptome zeigt, sind nahezu die Hälfte aller über 70-jährigen (mehr als 43%) betroffen (Abb. 1). Der Krankheitswert einzelner Miktionssymptome ist unterschiedlich zu bewerten. Nykturie, Harndrang und Pollakisurie werden im allgemeinen als störender empfunden als Restharngefühl, schwacher Harnstrahl oder Harnstottern. Von den Betroffnen werden etwa die Hälfte — zum Teil über mehrere Jahre — wegen ihrer Miktionsstörungen medikamentös behandelt. Sogenannte „Prostatamittel” stehen hier an erster Stelle, da — so wird unterstellt — die Mehrzahl der Betroffenen an prostatabedingten Miktionsstörungen leidet. An der Versorgung dieser Patienten sind hierzulande mehrere Fachgruppen beteiligt. Es verwundert daher nicht, dass große Unterschiede in der Anwendung diagnostischer und therapeutischer Maßnahem bestehen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abrams P, Schulman CC, Vaage S (1995) European Tamsulosin Study Group. Tamsulosin, a selective aIC-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic „obstruction” (symptomatic BPH). Br J Urol 76: 325–326

    Article  PubMed  CAS  Google Scholar 

  2. Altwein J, Aumüller G, Berges RR et al. (1999) Leitlinien der Deutschen Urologen zur Therapie des BPH-Syndroms. Urologe (A) 38(5)499–505

    Google Scholar 

  3. Andersen JT, Ekman P, Wolf H et al. (1995) Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 46(5): 631

    Article  PubMed  CAS  Google Scholar 

  4. Berges RR, Windeler J, Trampisch HJ, Senge T and The Beta-Sitosterol Study Group (1995) Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 345:1529–32

    Article  PubMed  CAS  Google Scholar 

  5. Berges RR, Pientka L (1999) Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 36 (Suppl 3): 21–27

    Article  PubMed  Google Scholar 

  6. Berges RR, Kassen A, Senge T (2000) Treatment of symptomatic benign prostatic hyperplasia with beta- sitosterol: an 18-month follow-up. Br J Urol Int 85(7): 842–846

    Article  CAS  Google Scholar 

  7. Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with Finasteride: meta-analysis of randomized clinical trials. Urology 48: 398–405

    Article  PubMed  CAS  Google Scholar 

  8. Boyle P, Robertson C et al. (2000) Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 55(4): 533–539

    Article  PubMed  CAS  Google Scholar 

  9. Brawer MK, Adams G, Epstein H (1993) Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 2: 929–935

    Article  PubMed  CAS  Google Scholar 

  10. Buzelin JM, Hebert M, Blondin P (1993) Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. Br J Urol 72: 922–927

    Article  PubMed  CAS  Google Scholar 

  11. Chapple CR et al (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74: 50–56

    Article  PubMed  CAS  Google Scholar 

  12. Chapple CR, Wyndaele JJ, Nordling J et al. (1996) Tamsulosin, the first prostate-selective alpha(1 A)-adrenoceptor antagonist — A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH) Eur Urol 29: 155–167

    PubMed  CAS  Google Scholar 

  13. Christensen MM, Holme JB, Rasmussen PC et al. (1993) Doxazosin treatment in patients with prostatic obstructions. Scand J Urol Nephrol 27: 39–44

    Article  PubMed  CAS  Google Scholar 

  14. Elhilali MM, Ramsey EW, Barkin J et al. (1996) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology. 1996;47,3: 335–42

    Article  Google Scholar 

  15. Eri LM, Tveter KJ (1995) Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 154: 923–934

    Article  PubMed  CAS  Google Scholar 

  16. Fawzy A et al. (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154: 105–109

    Article  PubMed  CAS  Google Scholar 

  17. Finasteride Study Group (1993) Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22: 291–299

    Article  Google Scholar 

  18. Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K, Dias N (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled dose-response multicenter study. J Urol 154: 110–115

    Article  PubMed  CAS  Google Scholar 

  19. Gormley GJ, Stoner E, Bruskewitz RC et al. (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Eng J Med 327: 1185–1191

    Article  CAS  Google Scholar 

  20. Hansen, Nordling J et al. (1994). Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, doubleblind, placebo-controlled trial. ALFECH Study Group. Scand J Urol Nephrol Suppl 157: 169–176

    PubMed  CAS  Google Scholar 

  21. Holme JB, Christensen MM, Rasmussen PC et al (1994) 29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 28: 77–82

    Article  Google Scholar 

  22. Italian Alfuzosin Cooperative Group (1995) Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient’s quality of life. Eur Urol 27: 128–134

    Google Scholar 

  23. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P (1993) Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12–18 month assessment. Br J Urol 72: 615–620

    Article  PubMed  CAS  Google Scholar 

  24. Jardin A, Bensodoun H, Delauche-Cavallier MC, Attali P (1991) Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337: 1457–1461

    Article  PubMed  CAS  Google Scholar 

  25. Jonas A, Rosenblat G et al. (1998) Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5alpha reductase activity, aromatase activity and lipid peroxidation. Urol Res 26(4): 265–70

    Article  PubMed  CAS  Google Scholar 

  26. Jonler M, Wasson JH, Reda DJ, Bruskewitz RC (1994) Analysis of watchful waiting studies. Progress in Clinical and Biological Research. In: Kurth K, Newling DWW (eds) Benign prostatic hyperplasia 386: 291–302

    Google Scholar 

  27. Kawachi I, Barry MJ, Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1996) The impact of different therapies on symptoms of benign prostatic hyperplasia: a prospective study. Clin Ther 18: 1118–1127

    Article  PubMed  CAS  Google Scholar 

  28. Klippel KF, Hilt! DM, Schipp B (1997) A multicentric, placebo- controlled, double-blind, clinical trial of ß-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 80: 427–432

    Article  PubMed  CAS  Google Scholar 

  29. Labasky RF (1996) Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement — Comment. J Urol 156: 1034

    Article  Google Scholar 

  30. Lepor H et al. (1992) Randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467

    PubMed  CAS  Google Scholar 

  31. Lepor H et al. (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335: 533–539

    Article  PubMed  CAS  Google Scholar 

  32. Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary AV, Kirk D (1992) Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br J Urol 70: 17–21

    Article  PubMed  Google Scholar 

  33. Lowe FC, Dreikorn K et al. (1998) Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37(3): 187–193

    Article  PubMed  CAS  Google Scholar 

  34. Lukacs B, McCarthy C, Grange JC, and The QOL BPH Study Group in General Practice (1993) Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. Eur Urol 24: 34–40

    PubMed  Google Scholar 

  35. Lukacs B (1999) Management of symptomatic BPH in France: who is treated and how? Eur Urol 36(Suppl 3): 14–20

    Article  PubMed  Google Scholar 

  36. MacDonald R, Ishani A et al. (2000) A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int 85(7): 836–841

    Article  PubMed  CAS  Google Scholar 

  37. Marks LS, Partin AW et al. (2000) Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 163(5): 1451–1456

    Article  PubMed  CAS  Google Scholar 

  38. Martelli A, Pacifico P, Casadei G (1993) Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Eur Urol 24: 28–33

    PubMed  Google Scholar 

  39. McConnell J, Bruskewitz R, Walsh P et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338: 557–63

    Article  PubMed  CAS  Google Scholar 

  40. Nacey JN, Meffan PJ, Delahunt B (1995) The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia. Aust N Z J Surg 65: 35–39

    Article  PubMed  CAS  Google Scholar 

  41. Neal DE (1997) Watchful waiting or drug therapy for benign prostatic hyperplasia. Lancet 350: 305–306

    Article  PubMed  CAS  Google Scholar 

  42. Nickel JC, Fradet Y, Boake RC et al. (1996) Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 15(9): 1251–1259

    Google Scholar 

  43. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, Padley RJ (1996) The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 47(2): 159–168

    Article  PubMed  CAS  Google Scholar 

  44. Sall M, Bruskewitz R (1996) Treatment of benign prostatic hyperplasia: surgery, medical therapy, or watchful waiting. Compr Ther 22: 554–558

    PubMed  CAS  Google Scholar 

  45. Schulman CC, Cortvriend J, Jonas U, Lock TMTW, Vaage S, Speakman MJ, on behalf of the European Tamsulosin Study Group (1996) Tamsulosin, the first prostate-selective alpha(1 A)adrenoceptor antagonist — Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 29: 145–154

    PubMed  CAS  Google Scholar 

  46. Schulman CC, de Sy W, Vandendries M, Tomas M, Santoni JP (1994) Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. Acta Urol Belg 62(4): 15–21

    PubMed  CAS  Google Scholar 

  47. Sökeland J, Albrecht J (1997) Kombination aus Sabal-und Urticaextrakt versus Finasterid bei BPH (Stadium I-III nach Alken) Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie. Urologe A 36: 327–333

    Article  PubMed  Google Scholar 

  48. Sokeland J, Albrecht J (1997) Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II) Comparison of therapeutic effectiveness in a one year double-blind study (see comments). Urologe A 36(4): 327–333

    Article  PubMed  CAS  Google Scholar 

  49. Stoner E (1994) Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group. Arch Intern Med 154: 83–88

    Article  PubMed  CAS  Google Scholar 

  50. Stoner E (1994) Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 43: 284–294

    Article  PubMed  CAS  Google Scholar 

  51. The Finasteride Study Group (1993) Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 22: 291–299

    Article  Google Scholar 

  52. The Italian Alfuzosin Cooperative Group (1995) Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient’s quality of life. Eur Urol 27: 128–134

    Google Scholar 

  53. Tubaro A, Montanari E (1999) Management of symptomatic BPH in Italy: who is treated and how?” Eur Urol 36(Suppl 3) : 28–32

    Article  PubMed  Google Scholar 

  54. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG (1995) A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 332: 75–79

    Article  PubMed  CAS  Google Scholar 

  55. Wilt TJ, Ishani A et al. (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review . JAMA 280(18): 1604–1609

    Article  PubMed  CAS  Google Scholar 

  56. Wilt TJ, Ishani A et al. (1999) Beta-sitosterols for for the treatment of benign prostatic hyperplasia: a systemic review. BJU Int 83: 976–983

    Article  PubMed  CAS  Google Scholar 

  57. Wilt TJ, Ishani A et al. (2000) Serenoa repens for benign prostatic hyperplasia. Cochr Datab Syst Rev 2

    Google Scholar 

  58. Wilt TJ, MacDonald R, Ishani A, Rutks I (2000) A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. Br J Urol Int 85: 836–841

    Google Scholar 

  59. Witjes WPJ, de Wildt MJAM, Rosier PFWM, Caris CTM, Debruyne FMJ, de la Rosette JJMCH (1996) Variability of clinical and pressure-flow study variables after 6 month of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement. J Urol 156: 1026–1034

    Article  PubMed  CAS  Google Scholar 

  60. Yu HJ, Chiu TY, Lai MK (1995) Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial. J Formos Med Assoc 94(1/2): 37–41

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. R. Berges
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Urologische Klinik und Poliklinik, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Michael C. Truss , Christian G. Stief , Stefan Machtens  & Udo Jonas (Direktor), ,  &  (Direktor)

  2. Zentrum Anästhesiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland

    Till Wagner

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Berges, R. (2002). Pharmakologische Therapie von prostatabedingten Miktionsstörungen. In: Truss, M.C., Stief, C.G., Machtens, S., Jonas, U., Wagner, T. (eds) Pharmakotherapie in der Urologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-09273-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-09273-6_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41519-0

  • Online ISBN: 978-3-662-09273-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation